Company Directory

Jetbio has been established to commercialise Newcastle University’s patented and groundbreaking 3D bioprinting technology. The company’s reactive jet impingement (ReJI) bioprinting technology creates fast, accurate, flexible and user-friendly systems for printing biomimetic cell filled gels for use in developing in vitro disease models for drug testing, and to support tissue engineering and regenerative medicine applications.

3D bioprinting is a promising technique for drug discovery because it can create models that more closely mimic human organs and tissues than traditional methods. These models can help identify potential drug side effects and can greatly reduce the time it takes to develop pharmaceutical treatments to ensure that ineffective drug compounds are eliminated from on-going drug development.

The company’s team combine a blend of skills in bioprinting research, manufacturing engineering, biomaterials and global business development. Collaborative projects with organisations has already delivered and validated the ReJI Jetbio technology with a number of end-users in industry and academic research resulting in Jetbio technology that will deliver robust 3D bioprinters and bioink products with high performance and competitive pricing.